Skip to main content
Home
Conference
Abstracts & Posters 2024
Totally RAD Award Winner
Education & Resources
Articles & Publications
Past Conferences
RAVE Abstracts and Posters - June 2024
About
Contact
Home
Conference
Abstracts & Posters 2024
Totally RAD Award Winner
Education & Resources
Articles & Publications
Past Conferences
RAVE Abstracts and Posters - June 2024
About
Contact
A Phase 2a study of amlitelimab, a novel non-depleting anti-OX40Ligand (OX40L) mAb in patients with moderate to severe atopic dermatitis (AD)